Clinical Trials Logo

Brief Resolved Unexplained Event clinical trials

View clinical trials related to Brief Resolved Unexplained Event.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04504227 Recruiting - Dysphagia Clinical Trials

Effect of Thickened Feeds on Swallow Physiology in Children With Dysphagia

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This study will examine the effects of varying liquid viscosity on swallow physiology in infants with oropharyngeal dysphagia and brief resolved unexplained event (BRUE) and other children with dysphagia that would be at risk for symptoms of swallow dysfunction.

NCT ID: NCT04477460 Recruiting - Clinical trials for Oropharyngeal Dysphagia

Effect of Thickened Feeds on Clinical Outcomes in Children With Brief Resolved Unexplained Event

BRUE
Start date: April 1, 2021
Phase:
Study type: Observational

This observational study will examine the effects of thickened feeds on clinical outcomes and healthcare utilization in infants with brief resolved unexplained event (BRUE).

NCT ID: NCT03278977 Recruiting - Clinical trials for Apparent Life-Threatening Event in Infants Under One Year of Age

Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors

iALTE
Start date: September 15, 2018
Phase: N/A
Study type: Interventional

Apparent Life-Threatening Events (ALTE) in infants often lead to severe neurological complications or to sudden death. In such situations, cardio-pediatricians and intensive care physicians have no specific diagnosis or treatment. In a recent translational research (INSERM-DHOS), our team has reported a myocardiac abnormality in a rabbit model of vagal hyperreactivity which is also present in the human hearts of infants deceased from sudden death, i.e. increased M2 muscarinic receptors (M2R) density associated with compensative increased enzymatic activity and overexpression of acetylcholine esterase (AchE). In a recent PHRC-I study (article in preparation), these abnormalities have also been observed in the blood of patients, infants as well as adults, exhibiting severe vagal syncopes. We observed, even more importantly, similar abnormalities in infants under 1 year of age with very severe idiopathic ALTE (iALTE) compared with normal subjects and with patients who presented ALTE with identified etiologies (JAMA Pediatric, 2016 May). The aim of this present study is to validate the overexpression of M2R as a marker of risk of iALTE in infant under 1 year.